Category - Executive Moves

Executive Moves

Wall Street veteran, Jason Kolbert, joins HCW

Jason Kolbert, a former a senior managing director with the Maxim Group, and the head of healthcare research as well as a covering analyst, has joined H.C. Wainwright as a managing director of research.

April 3, 2018

Executive Moves

FUF newsletter features interview with Profound Medical CEO, Arun Menawat

Focused Ultrasound Foundation’s newsletter has published an interview with Arun Menawat, CEO of Profound Medical (OTCQX:PRFMF; TSXV:PRN), in which he discusses the company’s transformation during the past two years and...

March 23, 2018

Executive Moves

Soricimed names Dr. Marc Rubin and Vaughn Embro-Pantalony to board

Closely-held Soricimed Biopharma has appointed accomplished biotech and pharma Industry veterans, Marc Robin, MD and Vaughn Embry-Pantalony to its board, effective immediately. In a statement, Tom Reeves, chairman, said...

March 20, 2018

Executive Moves

NY investment community veteran, Miranda Toledano, joins HCW in Israel

Miranda Toledano has joined H.C. Wainwright's healthcare investment banking team where she will focus on building out the firm's footprint across Europe and Israel.

February 15, 2018

Executive Moves

Eiger BioPharma names Eldon Mayer to board

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Eldon Mayer as a director, while Chuck Bramlage has left the board to focus on a newly accepted position as CEO at another start-up company.

January 8, 2018

Executive Moves

Ortho RTi names Sharon Ludlow as a director

Ortho Regenerative Technologies (CSE:ORTH) appointed Sharon Ludlow to the board, succeeding Laurence Rulleau, who has resigned.

January 8, 2018

Executive Moves

Eiger BioPharma names Dr. David Apelian as COO, EMO

Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Dr. David Apelian as chief operating officer and executive medical officer.

January 3, 2018

Executive Moves

Analysts start Quanterix at OP, buy; PTs $27, $26

Analysts at Leerink and BTIG launched coverage of Quanterix (NASDAQ:QTRX) with “outperform” and “buy” ratings, respectively, and price targets of $27 and $26, respectively. The stock closed at $21.47 on Dec. 29.

January 2, 2018

Executive Moves

Ortho RTi appoints Dr. Jacques Toueg to SAB

Ortho Regenerative Technologies (CSE:ORTH) appointed Dr. Jacques Toueg to its scientific advisory board (SAB).

December 19, 2017

Executive Moves

Rubius Therapeutics names Andrew Oh as CFO

Closely-held Rubius Therapeutics appointed Andrew Oh, who has more than 20 years of experience in finance and the biopharmaceutical industry, as CFO.

December 18, 2017

Category - Executive Moves

Wall Street veteran, Jason Kolbert, joins HCW

FUF newsletter features interview with Profound Medical CEO, Arun Menawat

Soricimed names Dr. Marc Rubin and Vaughn Embro-Pantalony to board

NY investment community veteran, Miranda Toledano, joins HCW in Israel

Eiger BioPharma names Eldon Mayer to board

Ortho RTi names Sharon Ludlow as a director

Eiger BioPharma names Dr. David Apelian as COO, EMO

Analysts start Quanterix at OP, buy; PTs $27, $26

Ortho RTi appoints Dr. Jacques Toueg to SAB

Rubius Therapeutics names Andrew Oh as CFO

General

More